Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Mar 15;12(3):40. doi: 10.1038/s41408-022-00641-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Age profile of patients with ITP, AA, and MDS. B The prevalence of CH in ITP was much lower than that in AA and hMDS. C The VAF value of mutations in ITP patients was much lower than that in AA and hMDS. D Mutation number distribution in all CH patients. E The gender ratio of patients with ITP, AA, and hMDS. F The prevalence of CH in ITP patients over 65 years old was higher than that under 65 years old (27.27% vs. 6.25%, P = 0.005). The polyline represents the cumulative prevalence of CH in ITP patients, the bars show the percentage of patients with CH in different age groups. G No statistically significant correlation was found between mutation VAF and age in ITP patients. H The prevalence of different genes in ITP patients with CH or with low-burden mutations. I The top six most frequently mutated genes in AA patients with CH. J The top six most frequently mutated genes in hMDS patients with CH. K The percentages of different mutation types in all mutations. L There was no statistical difference in the platelet count between CH and non-CH-ITP patients (9.82 ± 7.77 vs. 18.07 ± 16.04, P = 0.097). M Severe bleeding cases occurred in 36.4% CH-ITP patients and 8.8% non-CH-ITP patients. The platelet count and patient age were included in the confounders in the analysis. N The initial response rate in patients with CH was lower compared with patients without CH though it did not reach statistical significance. The proportion of refractory cases in patients with CH was much higher than that in non-CH patients. All data analyzed by t test were normally distributed and similar in variance. CH clonal hematopoiesis, VAF variant allele frequency, del deletion, dup duplication, ins insertion, delins deletion-insertion.